Drug Profile
Rislenemdaz - Avalo Therapeutics
Alternative Names: AVTX-301; CERC-301; MK-0657Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Avalo Therapeutics; Merck & Co
- Class Amines; Antidepressants; Antihypotensives; Antiparkinsonians; Esters; Piperidines; Pyrimidines
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
- No development reported Orthostatic hypotension
- Discontinued Parkinson's disease